R3 Vascular recently announced that the first patient in its ELITE-BTK pivotal trial has been treated by Brian DeRubertis, chief of vascular surgery at New York-Presbyterian and Weill Cornell Medicine in New York City.
The trial evaluates R3 Vascular’s next-generation drug-eluting bioresorbable scaffold, Magnitude, for below-the-knee (BTK) peripheral arterial disease (PAD).
DeRubertis commented on the importance of the ELITE-BTK pivotal trial, saying: “I have spent much of my career researching novel devices for vascular disease, including bioresorbable scaffolds, and, while there have been some recent successes in the BTK PAD trial landscape, there remain significant unmet needs in this area.
“We expect the results of this important trial will reveal Magnitude’s unique potential to further advance treatment and improve patient outcomes for patients with vascular disease.”
